Home > News Center
 
Contact Us
Shanghai BravoBio Co., Ltd.
Add: Suite 14E, Building #5, Haifu Garden, 1365 Dongfang Road, Lujiazui Financial and Trade Zone, Shanghai 200127, China
Tel: +86 21 2025 5516
Fax: +86 21 2025 5517
Email: bd@bravobio.com
News Center
 
Which pharmaceutical company is admirable?
Mar. 19, 2012
 
According to Fortune (March 19, 2012 issue), the World's Most Admired Company in pharmaceutical industry is Novartis, followed by Abbott Laboratories, Bristol-Myers Squibb, Merck, Johnson & Johnson, Roche Group and GlaxoSmithKline. Amgen, Pfizer, Boehringer Ingelheim, Sanofi-Aventis, AstraZeneca and Eli Lilly ranked 8~13.
 
5th Annual BioPharma Asia Convention 2012 held in Singapore
Mar. 23, 2012
 
BravoBio took part in the event in Marina Bay Sands, Singapore. Dr. Ke Wu was invited to give a presentation on improving the quality of human vaccines. He also attended the CEO breakfast forum sponsored by Innovation Ireland.
 
BravoBio, the Trailblazer
Mar. 24, 2012
 
In the Issue 3, Vol 7 of BioSpectrum Asia Edition, published in March 2012, BravoBio was listed as one of the Trailblazers in Asia.
 
BravoBio's new space in Biolake
Apr. 13, 2012
 
BravoBio will acquire a pilot scale laboratory located in Biolake, Wuhan National Bio-industry Base. BravoBio will have its process development, formulation and analytical studies for a cluster of human new vaccines there.
 
"Infection and Immune Conference 2012" held in Chongqing
Apr. 21, 2012
 
Hosted by Medical Microbiology and Immunology Professional Committee, Chinese Society of Microbiology (CSM), the conference attracted over 200 scientists and representatives from Chinese Academy of Sciences, universities, medical colleges, institutes and NGOs. Dr. Wu Ke was invited to be the Committeeman for another 5 years by CSM.
 
About 300 vaccines in R&D stage in USA
Apr. 29, 2012
 
According to Pharmaceutical Research and Manufacturers of America (PhRMA), US biopharmaceutical companies are developing 170 new vaccines against infectious diseases, 102 for cancers and 8 for neurological disorders. All of the vaccines are currently in clinical trials or under review at the Food and Drug Administration (FDA). This may metaphor a trend of biopharmaceutical and also a much brighter future of the industry.
 
GAVI is to deal with HPV business
May 7, 2012
 
According to Reuters, GAVI is nearing a price deal with GlaxoSmithKline and Merck for human papillomavirus (HPV) vaccines. If negotiations are successful, up to 2 million females in 9 developing countries could be protected from cervical cancer by 2015.
 
First Phase III cancer vaccine in EU
May 16, 2012
 
According to the U.K.'s Daily Telegraph, Bavarian Nordic's therapeutic prostate cancer vaccine, PROSTVAC, has started a Phase III trial in the U.K. The poxvirus-based vaccine includes the DNA sequence for a section of the prostate-specific antigen (PSA). This is the first cancer vaccine to have made it to Phase III in Europe.
 
Top 10 Best-selling Cancer Drugs in US
May 20, 2012
 
According to IMS Health, the top-selling cancer drugs in US market in 2011 are: Rituxan ($3 billion), Avastin ($2.66 billion), Herceptin ($1.66 billion), Gleevec ($1.51 billion), Eloxatin ( $1.2 billion), Alimta ($1.04 billion), Erbitux ($703.3 million), Velcade ($692.7 million), Xeloda ($647.6 million) and Tarceva ($564.2 million).
Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Next